Jakafi

Primary Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera + 10 more
Treatment
19 FDA approvals
20 Active Studies for Jakafi

What is Jakafi

RuxolitinibThe Generic name of this drug
Treatment SummaryRuxolitinib, also known as Jakafi, is a drug used to prevent cell growth and treat certain types of blood cancer and other immune system diseases. It was first approved by the FDA in 2011 and is used to treat myelofibrosis and polycythemia vera. In 2019, it was also approved for use in adults and children with steroid-refractory acute graft-versus-host disease, and in 2021 for mild to moderate atopic dermatitis. Ruxolitinib works by blocking the JAK1 and JAK2 tyrosine kinases responsible for cytokine signalling and he
Jakafiis the brand name
image of different drug pills on a surface
Jakafi Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Jakafi
Ruxolitinib
2011
6

Approved as Treatment by the FDA

Ruxolitinib, otherwise called Jakafi, is approved by the FDA for 19 uses like refractory Polycythemia vera and Post Polycythemia Vera Myelofibrosis .
refractory Polycythemia vera
Helps manage refractory Polycythemia vera
Post Polycythemia Vera Myelofibrosis
Helps manage Post Polycythemia Vera Myelofibrosis
high risk Myelofibrosis
Helps manage high risk Myelofibrosis
intermediate risk Myelofibrosis
Helps manage intermediate risk Myelofibrosis
Chronic Graft Versus Host Disease
Helps manage Chronic Graft Versus Host Disease
Primary Myelofibrosis (PMF)
Helps manage Primary Myelofibrosis (PMF)
Post Essential Thrombocythaemia Myelofibrosis
Helps manage Post Essential Thrombocythaemia Myelofibrosis
Acute Graft-Versus-Host Disease (GVHD)
Helps manage Acute Graft-Versus-Host Disease (GVHD)
resistant to or intolerant of hydroxyurea
Helps manage resistant to or intolerant of hydroxyurea
Polycythemia
Helps manage Post Polycythemia Vera Myelofibrosis
Polycythemia Vera
Helps manage refractory Polycythemia vera
Primary Myelofibrosis
Helps manage high risk Myelofibrosis
Disease
Helps manage Chronic Graft Versus Host Disease
Primary Myelofibrosis
Helps manage Primary Myelofibrosis (PMF)
Primary Myelofibrosis
Helps manage intermediate risk Myelofibrosis
Disease
Helps manage failure of at least one prior systemic therapy
Primary Myelofibrosis
Helps manage Post Essential Thrombocythaemia Myelofibrosis
Steroid Refractory
Helps manage Steroid Refractory
Graft-vs-Host Disease
Helps manage Acute Graft-Versus-Host Disease (GVHD)

Effectiveness

How Jakafi Affects PatientsRuxolitinib is a medicine used to treat different kinds of blood cancer. It works by stopping cells from growing and dividing, killing cancer cells, and lowering inflammation in the body. In clinical trials, ruxolitinib was found to reduce the size of the spleen and improve symptoms of myelofibrosis. Studies on mice have also shown that it can help extend the lifespan of those with myeloproliferative neoplasms. Ruxolitinib works by blocking a protein called JAK2, which is found in both normal cells and cancer cells. However, some cancers, such as those with
How Jakafi works in the bodyThe Janus kinase (JAK) family of proteins helps control the way the body responds to growth factors and cytokines. These proteins are important for lymphocyte development and help regulate gene expression of pro-inflammatory cytokines. Ruxolitinib is a drug that blocks certain JAK proteins, thus preventing the body from responding in an excessive way to these cytokines and growth factors. In cancer cells, this can lead to cell death. This drug is also used to treat graft-versus-host-disease, an immune complication of allogeneic hematopoietic cell transplantation.

When to interrupt dosage

The advised dosage of Jakafi is contingent upon the recognized condition, including reluctance to or insensitivity to hydroxyurea, Steroid Refractory and Primary Myelofibrosis. Dosage varies according to the technique of administration (e.g. Cream - Topical or Oral) noted in the table below.
Condition
Dosage
Administration
Primary Myelofibrosis
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Primary Myelofibrosis
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Dermatitis, Atopic
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Polycythemia Vera
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Dermatitis, Atopic
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Steroid Refractory
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Disease
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Primary Myelofibrosis
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Primary Myelofibrosis
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Polycythemia
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Disease
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
resistant to or intolerant of hydroxyurea
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical
Graft-vs-Host Disease
, 5.0 mg, 10.0 mg, 15.0 mg, 20.0 mg, 25.0 mg, 0.015 mg/mg
, Oral, Tablet, Tablet - Oral, Cream, Cream - Topical, Topical

Warnings

There are 20 known major drug interactions with Jakafi.
Common Jakafi Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Antilymphocyte immunoglobulin (horse).
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ruxolitinib.
Baricitinib
Major
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Baricitinib.
Jakafi Toxicity & Overdose RiskThe lowest toxic dose of ruxolitinib in rats is 250mg/kg. Taking a single dose of up to 200mg is generally safe, but taking more than the recommended dose may lead to a decrease in white blood cells, red blood cells, and platelets. There is no known antidote for an overdose, so supportive treatment is advised. Hemodialysis will not help eliminate the drug from the body.
image of a doctor in a lab doing drug, clinical research

Jakafi Novel Uses: Which Conditions Have a Clinical Trial Featuring Jakafi?

23 active clinical trials are currently being conducted to determine the efficacy of Jakafi in managing Polycythemia, Primary Myelofibrosis and Related Disorders.
Condition
Clinical Trials
Trial Phases
Polycythemia
2 Actively Recruiting
Phase 3, Phase 1
Disease
9 Actively Recruiting
Phase 1, Phase 2, Not Applicable
resistant to or intolerant of hydroxyurea
0 Actively Recruiting
Primary Myelofibrosis
1 Actively Recruiting
Phase 2
Disease
0 Actively Recruiting
Primary Myelofibrosis
0 Actively Recruiting
Graft-vs-Host Disease
9 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable
Dermatitis, Atopic
0 Actively Recruiting
Steroid Refractory
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
Primary Myelofibrosis
0 Actively Recruiting
Polycythemia Vera
34 Actively Recruiting
Phase 2, Phase 4, Phase 3, Phase 1
Primary Myelofibrosis
1 Actively Recruiting
Phase 1

Jakafi Reviews: What are patients saying about Jakafi?

5Patient Review
11/18/2013
Jakafi for Myelofibrosis
Jakavi has been great a reducing the size of my spleen, but I unfortunately still experience all the other symptoms that come with myelofibrosis.
4.3Patient Review
10/31/2013
Jakafi for Myelofibrosis
I felt a significant difference within one week of starting this treatment regimen.
4Patient Review
9/8/2016
Jakafi for Myelofibrosis
Jakavi has been great in reducing the size of my spleen, but it hasn't done much for my platelet or hemoglobin counts. I get transfusions every month as a result. It's not ideal, but it's manageable.
3.3Patient Review
6/7/2012
Jakafi for Myelofibrosis
3Patient Review
5/28/2019
Jakafi for Myelofibrosis
This treatment was great for the first month, but then my spleen grew back to its original size and I gained 16 kg in 5 months.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about jakafi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Jakafi prescribed for?

"Jakafi is a medication used to treat adults with polycythemia vera who have already taken hydroxyurea but it was not effective enough or they could not tolerate it. Jakafi is also used to treat adults with certain types of myelofibrosis."

Answered by AI

What type of drug is Jakafi?

"Jakafi can either be used by itself or with other medications. It is classified as a Hematologic, a Kinase Inhibitor, and an Antineoplastic. It is not known if Jakafi is safe and effective for children under the age of 12."

Answered by AI

How long can you take Jakafi for?

"If you are taking Jakafi, your Healthcare Professional may allow up to 6 months to see if it is working for you. If you do not see an improvement after 6 months of treatment, your Healthcare Professional may have you stop taking Jakafi."

Answered by AI

Is Jakafi considered chemotherapy?

"Although Jakafi is not technically classified as chemotherapy, it does work to target and control the production of blood cells in a similar way."

Answered by AI

Clinical Trials for Jakafi

Have you considered Jakafi clinical trials? We made a collection of clinical trials featuring Jakafi, we think they might fit your search criteria.
Have you considered Jakafi clinical trials? We made a collection of clinical trials featuring Jakafi, we think they might fit your search criteria.
Have you considered Jakafi clinical trials? We made a collection of clinical trials featuring Jakafi, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top